Dr. Sol J. Barer, Ph.D. was named Chairman of the Board of Directors for the new Hackensack Meridian Health Center for Discovery and Innovation in June 2018. Dr. Barer currently serves as Chairman of the Board of Directors of Teva Pharmaceuticals. He is Managing Partner at SJ Barer Consulting and serves as an advisor to the Israel Biotech Fund. From 1987 to 2011, he served in top leadership roles at Celgene Corporation, including as Executive Chairman from 2010 to 2011, Chairman and CEO from 2007 to 2010, CEO from 2006 to 2010, President and Chief Operating Officer from 1994 to 2006 and President from 1993 to 1994. Prior to that, he was a founder of the biotechnology group at the chemical company Celanese Corporation, which was later spun off as Celgene. Dr. Barer serves on the board of directors of Contrafect as lead director. He previously served on the board of Aegerion Pharmaceuticals from 2011 to 2016, on the board of Amicus Therapeutics from 2009 to February 2017 and as Chairman of the Board of InspireMD from 2011 to June 2017. Dr. Barer is Chairman of the Board of Edge Therapeutics , Aevi Genomics (formerly Medgenics) and Centrexion Therapeutics.

David Perlin, Ph.D. is the founding Chief Scientific Officer and Senior Vice President for the Hackensack Meridian Health Center for Discovery and Innovation. He is a highly accomplished senior administrator and biomedical researcher focused on infectious diseases, cancer, transplant and other high-risk patients. Dr. Perlin is an expert in drug discovery and drug resistance mechanisms, and he has helped develop novel therapeutics and diagnostics against high threat bacteria, viruses, and fungi. He has published more than 300+ papers and book chapters, and has co-authored two books. His laboratory is supported by multiple grants from the NIH, Pharma and biopharma sectors.

David S. Siegel, MD, PhD, is one of the nation’s foremost authorities on multiple myeloma (a blood cancer) and is founding Director of the Multiple Myeloma Institute. His research focuses on multiple myeloma, Waldenstrom’s macroglobulinemia, and AL amyloidosis. He has served as the lead investigator of the pivotal phase IIb study that led to the U.S. Food and Drug Administration’s approval of Kyprolis (carfilzomib) for recurrent multiple myeloma. Dr. Siegel helped bring Velcade (bortezomib) to multiple myeloma patients through his clinical trials showing that this medication slows and halts the progression of multiple myeloma. He has been involved in clinical trials that led to the approval of Thalomid (thalidomide), Revlimid (lenalidomide), Pomalyst (pomalidomide), Ninlaro (Ixazomib), Empliciti (elotuzumab), and Farydak (panobinostat). Dr. Siegel has led the John Theurer Cancer Center’s program to offer CAR T-cell therapy to patients with multiple myeloma. Finally, he is a member of the Multiple Myeloma Research Consortium Steering Committee, which promotes novel, cutting-edge treatments for patients afflicted by multiple myeloma.

Andre Goy, M.D., M.S., is Chairman and Director of John Theurer Cancer Center (JTCC) at Hackensack University Medical Center. As Chief of the Division of Lymphoma, he leads New Jersey’s largest program for lymphoma treatment and research. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute. Widely known for his work in mantle cell lymphoma, Dr. Goy was the lead investigator in the development of three FDA-approved drugs for this disease: bortezomib, lenalidomide, and ibrutinib. He participated in the pilot study of rituximab, which has improved the treatment of B-cell lymphoma, leukemia, and autoimmune disorders. In his current research, Dr. Goy is assessing biomarkers for lymphoma as well as novel anticancer agents, drug combinations, and non-chemotherapy options. Under Dr. Goy’s direction, JTCC became one of the few sites in the country offering chimeric antigen receptor (CAR) T-cell therapy—a highly promising immunotherapy for certain blood cancers.

CDI BOARD MEMBERS